Purple biotech achieves manufacturing milestone for im1240, a tri-specific antibody from the captn-3 platform

Achieved commercially viable yield for im1240, positioning the program competitively for future development validates scalability of the captn-3 tri-specific antibody platform im1240, the first captn-3 tri-specific antibody targeting the novel tumor-associated antigen 5t4, advances toward first-in-human clinical trials, with an investigational new drug (ind) submission planned for 2026 rehovot, israel, oct. 29, 2025 (globe newswire) -- purple biotech ltd. (“purple biotech” or the “company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the achievement of a manufacturing milestone for im1240, a tri-specific antibody from the captn-3 platform, which targets the tumor-associated antigen 5t4, the activating receptor cd3 on t cells and the inhibitory receptor nkg2a on nk and cd8⁺ t cells.
PPBT Ratings Summary
PPBT Quant Ranking